2-bromo-N-(5- chloropyridin-2- yl)propanamide | 1331868-60-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-bromo-N-(5- chloropyridin-2- yl)propanamide
• 英文别名: 2-bromo-N-(5-chloropyridin-2-yl)propanamide
• CAS: 1331868-60-0
• 化学式: C₈H₈BrClN₂O
• 分子量: 263.521
• InChiKey: LUHMKUYLPBASRT-UHFFFAOYSA-N

物化性质

• 沸点：
  398.3±37.0 °C(Predicted)
• 密度：
  1.670±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  42
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-N-(5- chloropyridin-2- yl)propanamide 、 1-(4-甲氧基-苯基)-1H-苯并咪唑-2-硫醇 在 potassium hydroxide 作用下， 以 乙醇 为溶剂， 反应 2.0h， 生成 N-(5-chloropyridin-2-yl)-2-((1-(4-methoxyphenyl)-1H-benzo[d]imidazol-2-yl)thio)propanamide
  参考文献：
  名称：

  Host-Directed Inhibitors of Myxoviruses: Synthesis and in Vitro Biochemical Evaluation

  摘要：

  Drugs targeted to viral proteins are highly vulnerable to the development of viral resistance. One little explored approach to the treatment of viral diseases is the development of agents that target host factors required for virus replication. Myxoviruses are predominantly associated with acute disease and, thus, ideally suited for this approach since the necessary treatment time is anticipated to be limited. High-throughput screening previously identified benzimidazole 22407448 with broad antiviral activity against different influenza virus and paramyxovirus strains. Hit to lead chemistry has generated 6p (JMN3-003) with potent antiviral activity against a panel of myxovirus family members exhibiting EC(50) values in the low nanomolar range.

  DOI：

  10.1021/ml200125r
• 作为产物：
  描述：

  2-氨基-5-氯吡啶 、 2-溴丙酰氯 在 sodium hydride 作用下， 以 四氢呋喃 、 mineral oil 为溶剂， 反应 4.0h， 以47.63%的产率得到2-bromo-N-(5- chloropyridin-2- yl)propanamide
  参考文献：
  名称：

  EP3686196

  摘要：

  公开号：

文献信息

• MRGX2 ANTAGONISTS
  申请人：GlaxoSmithKline Intellectual Property Development Limited

  公开号：US20220112174A1

  公开（公告）日：2022-04-14

  This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

  本发明涉及按照式（I）的新化合物，这些化合物是MrgX2的拮抗剂，包含它们的药物组合物，以及它们在治疗MrgX2介导的疾病和疾病中的应用。
• [EN] ANTAGONISTS OF MRGX2<br/>[FR] ANTAGONISTES DE MRGX2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2022152852A1

  公开（公告）日：2022-07-21

  This application relates to compounds of Formula (I), which are antagonists of MrgX2 (Mas-related Gene X2) and thus are useful as therapeutic agents, specifically therapeutic agents for use in the treatment of chronic spontaneous urticaria, mastocytosis, cold urticaria, atopic dermatitis, rosacea, Crohns disease, ulcerative colitis, irritable bowel syndrome, rheumatoid arthritis, fibromyalgia, nasal polyps, neuropathic pain, inflammatory pain, chronic itch, drug-induced anaphlactoid reactions, metabolic syndrome, oesophagus reflux, asthma, cough, or migraine.

  本申请涉及式（I）的化合物，它们是MrgX2（Mas相关基因X2）的拮抗剂，因此可用作治疗剂，具体用于治疗慢性自发性荨麻疹、肥大细胞增多症、寒冷性荨麻疹、特应性皮炎、酒渣鼻、克隆病、溃疡性结肠炎、肠易激综合征、类风湿性关节炎、纤维肌痛、鼻息肉、神经痛、炎症性疼痛、慢性瘙痒、药物诱导的过敏反应、代谢综合征、食管反流、哮喘、咳嗽或偏头痛的治疗剂。
• EP3686196
  申请人：——

  公开号：——

  公开（公告）日：——
• Host-Directed Inhibitors of Myxoviruses: Synthesis and in Vitro Biochemical Evaluation
  作者：Aiming Sun、J. Maina Ndungu、Stefanie A. Krumm、Jeong-Joong Yoon、Pahk Thepchatri、Michael Natchus、Richard K. Plemper、James P. Snyder

  DOI：10.1021/ml200125r

  日期：2011.11.10

  Drugs targeted to viral proteins are highly vulnerable to the development of viral resistance. One little explored approach to the treatment of viral diseases is the development of agents that target host factors required for virus replication. Myxoviruses are predominantly associated with acute disease and, thus, ideally suited for this approach since the necessary treatment time is anticipated to be limited. High-throughput screening previously identified benzimidazole 22407448 with broad antiviral activity against different influenza virus and paramyxovirus strains. Hit to lead chemistry has generated 6p (JMN3-003) with potent antiviral activity against a panel of myxovirus family members exhibiting EC(50) values in the low nanomolar range.